Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) recorded a 546% surge in profit attributable to shareholders in the first half to 36.9 million yuan from 5.7 million yuan a year prior.
Earnings per share increased to 0.0355 yuan from 0.0055 yuan previously, according to a Friday Hong Kong bourse filing.
Revenue slipped 4.6% to 372.2 million yuan from 390.1 million yuan a year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.